Definium Therapeutics (DFTX) Return on Equity (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Return on Equity data on file, last reported at 0.01% in Q1 2026.

• Quarterly Return on Equity changed 0.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (changed 0.0% YoY) and the FY2025 annual result came in at 0.01%, changed 0.0% from the prior year.
• Return on Equity climbed to 0.01% in Q1 2026 per DFTX's latest filing, from 0.01% in the prior quarter.
• Across five years, Return on Equity topped out at 0.0% in Q4 2022 and bottomed at 0.01% in Q4 2023.
• The 5-year median for Return on Equity is 0.0% (2024), against an average of 0.0%.
• The widest annual swing landed in 2023, when Return on Equity fell 1 bps; it then grew 1 bps in 2024.
• Tracing DFTX's Return on Equity over 5 years: stood at 0.0% in 2022, then slumped by 3273 bps to 0.01% in 2023, then surged by 63 bps to 0.0% in 2024, then tumbled by 85 bps to 0.01% in 2025, then grew by 12 bps to 0.01% in 2026.
• Per Business Quant, the three latest DFTX Return on Equity figures stand at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025).

Peer Comparison